When I was at the 2012 ICAAC in San Francisco last year, Trius Pharmaceuticals had extensive presentations on their two antibiotics.
The main interest for me was that they had a Gyrase program, similar to Biota's, and they were working very hard on it based on the presentation posters. I couldn't find another gyrase program presented.
Well, Trius looks like it will be sold to Cubist for at least 13.50 a share valuing the company at about 600 million. Which is about 4 times what it was worth a year ago when I was looking at their posters. It has about the same cash in the bank as BOTA, but is spending a lot more on its clinical Phase trials. Their gyrase is in Phase 1.
Their main antibiotic is tedizolid, which is a gram positive antibiotic with MRSA coverage. Its completed some Phase 3 trials in skin infections and they are extending its clinical scope.
I think the BOTA gyrase program might be worth something.
While a swallow doesn't make it spring, there have been a couple of them in the uplift in the share price of late.
The recent share price explosion experienced by companies like Biocryst and Trius gives us Biotans some hope.
ReplyDeleteI've always thought our Gyrase program might be worth something given Trius' program had attracted $30M funding support from an arm of the US govt.
Not sure what the differences are between our respective programs other than ours is IV/Oral and community based infections while theirs is IV and biodefense and community based infections???
Did Russell have much to say about this program at the recent briefings?
Not really.
ReplyDeleteIt wasn't mentioned in any detail at all. Much more attention was given to the HRV compound, and the DS situation, and I think we got clarification on that.
This was also Errington's compound, so not sure what the future holds.